Contact Us

Progenra Invited to Speak at Symposium “From Mechanisms to Therapeutic Insight in Neurodegeneration”

Nov 20, 2025, 10:30 AM Eastern Daylight Time

Progenra Drug Offers Hope for Therapy for Parkinson’s and Alzheimer’s disease

MALVERN, Pa. (Business Wire) — Neurodegenerative diseases present a global health challenge. Aggregation of proteins in neurons is the main cause of several neurodegenerative disorders. Tau protein aggregates for Alzheimer’s disease and alpha synuclein aggregates for Parkinson’s disease are prominent examples. 

Protein aggregates damage mitochondria leading to loss of ATP and neuronal cell death. Aggregated proteins or proteinapathies such as Lewy Body disease are also responsible for dementia.

Dr. Tauseef Butt of Progenra is invited to speak at the American Society of Cell Biology, meeting to be held at Philadelphia Convention Center, Philadelphia PA.

About 72 million people suffer from Alzheimer’s disease and dementia, 10 million people suffer from Parkinson’s disease, and about 2.5 million people suffer from multiple sclerosis. Stroke is the second leading cause of death world-wide. According to  Michael J Fox Foundation and Parkinson’s Foundation USA and National Institutes of Health/National Institutes of Aging.

The presentation details are as follows:
  • Session Title: From Mechanisms to Therapeutic Insight in Neurodegeneration
  • Session Date & Time: Tuesday, December 9 10:00 AM – 12: 00 PM
  • Room: Please visit the Cell Bio 2025 site for more details about the meeting.

Progenra Inc., has discovered a novel class of small-molecule PINK1 activators that restore mitochondrial function, a key regulator whose dysfunction leads to neurodegenerative diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Despite decades of research there is no drug that reverses PD symptoms. The small molecule drugs is a paradigm shift in Parkinson’s disease.

Since the PINK1 drug removes protein aggregates and restores mitochondrial health, its application for Lewy body disease and other proteinathies are also apparent. “This discovery opens an entirely new avenue for neurodegenerative diseases,” added Dr. Tauseef Butt, PhD, President& CEO of Progenra Inc.

About Progenra Inc:
Progenra (www.progenra.com), a biotech company, aims to develop novel medicines by exploring mitochondria and ubiquitin proteasome pathways. Progenra is developing novel modulators of PINK1/Parkin signaling pathway as therapeutics for antiaging, neurodegenerative and mitochondrial diseases such as Parkinson’s, Alzheimer’s as well as cardiovascular diseases.

Contacts Media: Sarah Thomas
bd@progenra.com
www.progenra.com
610-644-6974 x 310